INTRODUCTION
Methionine adenosyltransferase (MAT) is a critical cellular enzyme that catalyses the formation of S-adenosylmethionine (SAM), the principal biological methyl donor and the ultimate source of the propylamine moiety used in polyamine biosynthesis [1, 2] . In mammals, two different genes, MAT1A and MAT2A, encode two homologous MAT catalytic subunits, α1 and α2 [3] [4] [5] . MAT1A is expressed only in liver and encodes the α1 subunit found in two native MAT isozymes, which are either a dimer (MAT III) or tetramer (MAT I) of this single subunit [5] . MAT2A encodes a catalytic subunit (α2) found in a native MAT isozyme (MAT II), which is associated with a catalytically inactive regulatory subunit ( β) in lymphocytes encoded by a third gene [5] [6] [7] . MAT2A is distributed widely [3] [4] [5] .
Upon activation of T-lymphocytes, both the SAM pool size and the rate of SAM utilization increased [8] . Inhibition of SAM synthesis blocked T-lymphocyte proliferation [9] . A key mechanism for the increase in SAM biosynthesis is increased transcription of MAT2A [10, 11] . We cloned recently a 1.3 kb 5'-flanking region of the human MAT2A [12] . In the current work we investigated the molecular mechanism of increased MAT2A expression during activation of the human leukaemic T-cell line, Jurkat. This cell line is often used as an excellent model with which to study the activation of T-lymphocytes [13] and we have shown that the human MAT2A promoter was able to drive efficiently luciferase expression in these cells [12] . In the current study Jurkat cells were treated with interleukin-2 (IL-2), PMA Abbreviations used : EMSA, electrophoretic mobility-shift assay ; IL-2, interleukin-2 ; MAT, methionine adenosyltransferase ; PHA, phytohaemagglutinin ; PKC, protein kinase C ; SAM, S-adenosylmethionine. 1 To whom correspondence should be addressed (e-mail shellylu!hsc.usc.edu).
consensus binding site. c-Myb is known to be induced during Tlymphocyte activation and its mRNA level was increased after treatment of Jurkat cells with IL-2, PMA or PMA plus PHA. Increased nuclear binding to the MAT2A c-Myb site was confirmed on electrophoretic mobility-shift and supershift analyses. Mutation of the MAT2A c-Myb site abolished the stimulatory effect of these agents on c-Myb nuclear binding and MAT2A promoter activities. Overexpression of c-Myb increased MAT2A promoter activity by 2-fold. Dexamethasone, a known inhibitor of lymphocyte activation, blocked the effect of these agents on MAT2A expression by preventing the increase in c-Myb expression.
Research Center and grown according to instructions provided by the ATCC (Rockville, MD, U.S.A.). Jurkat cells were cultured in RPMI supplemented with 10 % fetal bovine serum, 2 mM -glutamine and 1 % penicillin\streptomycin mixture.
Recombinant plasmids
The human MAT2A promoter constructs containing 5' deletions as described in [12] were subcloned in the sense orientation upstream of the luciferase coding sequence of the pGL-3 enhancer vector (Promega). MAT2A promoter construct mutated in the putative c-Myb site (k350 to k333 ; from 5'-CGGCCAAC-GGTCGGAAGG-3' to 5'-CGCGTGCTAGCCCGGGCT-3', with the mutated bases underlined) was generated by using PCR as follows. (i) Upper fragment clone : forward primer (5'-ATCCCGGGGCCGGCAACG-3', k571 to k554 bp) and reverse primer (5'-GGGATAGCTTTCCCGGAGG-3', k349 to k369 bp) were used to amplify the k571 to k349 bp fragment from the MAT2A k571\j60 promoter construct [12] . PCR cycle parameters were 94 mC for 30 s, 58 mC for 40 s and 72 mC for 1 min, for 30 cycles. This PCR fragment was subcloned into the pGL-3 enhancer vector by first digesting the pGL-3 enhancer vector with MluI to generate 5'-protruding ends, which were then filled with T4 polynucleotide kinase, and treated with alkaline phosphatase to remove the 5'-terminal phosphate groups prior to the ligation reaction. This clone was called pGL-3-1.
(ii) For generation of the c-Myb mutant MAT2A construct, forward primer (5'-GAGGTGCCATGTCACCGC-3', k332 to k314 bp) and reverse primer (5'-GCTCGCGACAGCGTTCTACTC-3', j60 to j81 bp) were used to amplify the k332 to j60 bp fragment from the MAT2A k571\j60 promoter construct [12] . PCR cycle parameters were 94 mC for 30 s, 56 mC for 50 s and 72 mC for 1 min, for 30 cycles. This PCR fragment was subcloned into the pGL-3-1 vector (containing the upper fragment, k571 to k349 bp of MAT2A, as described above) by digesting the pGL-3-1 vector with XhoI to generate 5'-protruding ends, which were then filled with T4 polynucleotide kinase, and treated with alkaline phosphatase to remove the 5'-terminal phosphate groups prior to the ligation reaction. In so doing, the putative c-Mybbinding site, k350 to k333 bp of the MAT2A (5'-CGGCCA-ACGGTCGGAAGG-3'), was replaced by the MluI-XhoI fragment of the pGL-3 enhancer vector (5'-CGCGTGCTAGCCC-GGGCT-3'). All sequences were confirmed by dideoxy sequencing. The c-Myb expression vector, pMTHMb, driven by a mouse metallothionein-I promoter, was provided kindly by Dr Michael Kuehl (National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.) [15] .
Transfection assays
Jurkat cells (6i10' cells in 4 ml of medium) were transiently transfected with 8 µg of MAT2A promoter-luciferase constructs or the promoterless pGL-3 enhancer vector (as a negative control) and 2 µg of a β-galactosidase expression plasmid (as an internal standard of transfection efficiency) using Superfect Transfection Reagent (Qiagen, Valencia, CA, U.S.A.), as we described in [12] . After 24 h, cells were harvested and lysed in 1 ml of reporter lysis buffer (Luciferase Assay System, Promega). The luciferase assay was performed on 20 µl of the cleared lysate and 100 µl of luciferase assay reagent using a TD-20\20 Luminometer (Promega). The β-galactosidase assay was done according to the supplier's instructions ( β-Galactosidase Enzyme Assay System, Promega) using 150 µl of the cell lysate. Protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad). The luciferase activity of each transfection is expressed as the luciferase assay value normalized to the β-galactosidase activity and the protein concentration of each transfection.
To study the effects of IL-2, PMA and PMA plus PHA on MAT2A promoter activity, transfected Jurkat cells were treated with IL-2 (24 units\ml), PMA (50 ng\ml) or PMA (50 ng\ml) plus PHA (1 µg\ml) during the last 20 h of the transfection. These doses were chosen because they were shown to increase MAT2A expression in rat lymphoblasts [11] or to activate Jurkat cells [14] . In some experiments, cells were pretreated with dexamethasone (0.1 nM) for 30 min prior to adding IL-2 or PMA. To see if the effect of these agents on MAT2A promoter activity is mediated by c-Myb binding, cells were transfected with wild-type MAT2A k571\j60 promoter-luciferase construct or construct that was mutated in the putative c-Myb-binding site as described above. To see if c-Myb overexpression can influence MAT2A promoter activity, Jurkat cells were co-transfected with the c-Myb expression vector in the presence of ZnCl # (120 µM for 15 h) as described in [15] and either wild-type or c-Myb-sitemutated MAT2A promoter construct.
Nucleic acid extraction
RNA was isolated from Jurkat cells after various treatments according to the method of Chomczynski and Sacchi [16] . RNA concentration was determined spectrophotometrically before use and the integrity was checked by electrophoresis with subsequent ethidium bromide staining.
Northern-blot analysis
Northern-blot analysis was performed on total RNA using a specific MAT2A cDNA probe as described in [17] . A 580 bp human c-Myb cDNA probe, corresponding to nucleotides 380-961 of the published human c-Myb sequence [18] was obtained by reverse transcription and subsequent amplification by PCR. Primary PCR (forward and reverse primers were 5'-TCGAACAGATGTGCAGTGCCAG-3' and 5'-GTTCTGTG-TTGGTAGCACCTGC-3', respectively ; cycle parameters were 94 mC for 30 s, 60 mC for 1 min and 72 mC for 1 min, for 25 cycles) and secondary PCR (forward and reverse primers were 5'-GCTCATCAAGGGTCCTTGGACC-3' and 5'-GTCTCTGA-ATGGCTGCGGCTG-3', respectively ; cycle parameters were 94 mC for 30 s, 65 mC for 1 min and 72 mC for 1 min, for 28 cycles) were used to amplify the 580 bp human c-Myb cDNA probe. To ensure equal loading of RNA samples and transfer in each of the lanes, the same membranes were also rehybridized with $#P-labelled β-actin probe as described in [19] . All cDNA probes were labelled with [$#P]dCTP using a random-primer kit (PrimerIt II Kit ; Stratagene, La Jolla, CA, U.S.A.). Autoradiography and densitometry (Gel Documentation System, Scientific Technologies, Carlsbad, CA, U.S.A., and NIH Image 1.60 software) were used to quantify relative RNA. Results of Northern-blot analyses were normalized to β-actin.
Western-blot analysis of c-Myb
Western-blot analysis of the c-Myb protein level was done as described in [20] using total cell extracts as well as nuclear protein extracts from Jurkat cells treated with IL-2 (24 units\ml), PMA (50 ng\ml), PMA (50 ng\ml) plus PHA (1 µg\ml) or vehicle control for 20 h.
Electrophoretic mobility-shift assay (EMSA) and supershift assay
EMSAs for the putative binding sites were done as described in [20, 21] . Nuclear protein (15 µg) from Jurkat cells treated with IL-c-Myb up-regulates MAT2A expression in activated Jurkat cells 2 (24 units\ml), PMA (50 ng\ml), PMA (50 ng\ml) plus PHA (1 µg\ml) or vehicle control for 20 h were preincubated with 2 µg of poly(dI-dC) in a buffer containing 10 mM Hepes (pH 7.6), 50 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 5 mM MgCl # and 10 % glycerol for 10 min on ice. $#P-End labelled doublestranded DNA fragments (k354 to k328 of human MAT2A, wild-type or mutated at the c-Myb site as described above) were then added with or without a 100-fold excess of unlabelled specific probe as competitor. Mixtures were incubated for 20 min on ice, loaded on a 4 % non-denaturing polyacrylamide gel and subjected to electrophoresis in 50 mM Tris, 45 mM borate and 0.5 mM EDTA (pH 8.0). Further confirmation of the identity of the binding proteins was done by antibody supershift assay for c-Myb. Anti-c-Myb antibody (1.5 µl) was added to samples for 10 min before adding labelled probes, and mixtures were incubated for a further 20 min on ice before electrophoresis. Gels were dried and subjected to autoradiography.
Statistical analysis
Data are given as meanspS.E.M. For changes in mRNA levels, ratios of MAT2A or c-Myb to β-actin densitometric values were compared. For changes in protein levels, ratios of c-Myb to Coomassie Brilliant Blue-staining densitometric values were compared. Statistical analysis was performed using ANOVA followed by Fisher's test for multiple comparisons. Significance was defined as P 0.05.
RESULTS

Effect of IL-2, PMA, PMAjPHA on MAT2A expression in Jurkat cells
Treatment of Jurkat cells with IL-2 (24 units\ml), PMA (50 ng\ml), PMA (50 ng\ml) plus PHA (1 µg\ml) increased the steady-state mRNA level of MAT2A by about 2-fold (IL-2 l 190p9 %, PMA l 197p6 % and PMAjPHA l 186p6 % of the control by densitometric analysis, n l 3, P 0.05 by ANOVA ; Figure 1 ). Since increased MAT2A expression during T-lymphocyte activation was shown to be mediated largely by increased transcription [14] , we next examined the effect of these Progressive 5' deletions of the MAT2A promoter extending from k1329 to j60 bp were generated and fused to the promoterless luciferase pGL-3 enhancer vector as described in [12] . The construct k571/j60 was also mutated in the c-Myb site (k350 to k333 ; labelled as c-Myb mutation). Jurkat cells were transfected with these MAT2A promoter constructs and treated with IL-2 (24 units/ml), PMA (50 ng/ml), PMA (50 ng/ml) plus PHA (1 µg/ml) or vehicle control during the last 20 h of the transfection. Results represent meanspS.E.M. from three to five independent experiments performed in triplicate. The luciferase activity of each transfection is expressed as the luciferase assay value normalized to the β-galactosidase activity and the protein concentration of each transfection. Data are expressed as luciferase activity relative to that of the pGL-3 enhancer vector control, which was assigned a value of 1.0. *P 0.05 versus the pGL-3 enhancer control ; ßP 0.05 versus respective controls (ANOVA followed by Fisher's test).
agents on MAT2A promoter activity. Figure 2 shows that these treatments increased the reporter activity driven by the MAT2A promoter-luciferase constructs k571\j60, k939\j60 and k1329\j60 by nearly 2-fold but had no effect on the activity driven by the k270\j60-luciferase construct. This suggests the signalling mechanism lies within the region k571 to k270.
Effect of IL-2, PMA and PMAjPHA on c-Myb expression in Jurkat cells
The region between k571 and k270 of the human MAT2A contains numerous consensus binding sites for various transcription factors [12] . One that stands out is c-Myb (k350 to k333), since it is known to be induced during T-lymphocyte activation [14] . Consistent with this, treatment of Jurkat cells with IL-2, PMA and PMA plus PHA all increased the steadystate mRNA level of c-Myb by 2-3-fold (IL-2 l 285p15 %, PMA l 269p21 % and PMA plus PHA l 275p10 % of the control by densitometric analysis, n l 3, P 0.05 ; Figure 1) . A comparable increase in the c-Myb protein level was observed in the total cell extracts but a much more significant increase was seen in the nuclear protein extracts ($ 4-5-fold increase ; Figure 3 ).
Role of c-Myb in the up-regulation of MAT2A expression in Jurkat cells
To examine if the c-Myb site was critical for mediating the effect of IL-2, PMA and PMA plus PHA, Jurkat cells were transfected with the MAT2A k571\j60 promoter-luciferase construct,
Figure 3 Effect of IL-2, PMA and PMA/PHA on c-Myb protein levels in total cell extracts or nuclear protein fraction
Cell extracts (50 µg of protein/lane) and nuclear protein (10 µg/lane) obtained from Jurkat cells treated with IL-2 (24 units/ml), PMA (50 ng/ml), PMA (50 ng/ml) plus PHA (1 µg/ml) or vehicle control (Con) for 20 h were analysed by Western-blot analysis using anti-c-Myb antibodies as described in the Materials and methods section. Equivalent protein loading was assured by Coomassie Brilliant Blue staining of gels after transblotting (results not shown). Representative blots from n l 3 are shown.
Table 1 Effect of co-transfection with the c-Myb expression vector, or dexamethasone (DEX) pretreatment on IL-2-and PMA-mediated induction of MAT2A promoter activity
Results represent meanspS.E.M. from three to five independent experiments performed in triplicate. In one series of experiments, Jurkat cells were co-transfected with the c-Myb expression vector and MAT2A promoter construct k571/j60, wild-type or mutated in the c-Myb-binding site, as described in the Materials and methods section. In another series of experiments, Jurkat cells were transfected with the MAT2A promoter construct k571/j60, treated with dexamethasone (DEX ; 0.1 nM), IL-2 (24 units/ml), PMA (50 ng/ml) or vehicle for 20 h. The effect of dexamethasone on IL-2-and PMA-mediated induction of MAT2A promoter activity was evaluated by pretreating cells with dexamethasone (0.1 nM) for 30 min prior to adding IL-2 or PMA. Data are expressed as relative luciferase activity to that of the pGL-3 enhancer vector control, which was assigned a value of 1.0.
Plasmid treatment
Relative containing a mutated putative c-Myb site (5'-CGGCCAAC-GGTCGGAAGG-3' to 5'-CGCGTGCTAGCCCGGGCT-3'). Figure 2 shows that mutation of the c-Myb site abolished the stimulatory effect of these agents on reporter activity. The role of c-Myb was confirmed further by co-transfecting Jurkat cells with a c-Myb expression vector. Table 1 shows that overexpression of c-Myb in quiescent Jurkat cells increased reporter activity driven by the MAT2A k571\j60 promoter construct by 2-fold but not if the c-Myb site was mutated.
Finally, EMSA and supershift analyses were used to demonstrate increased nuclear-binding activity to the MAT2A cMyb site after treatment of Jurkat cells with IL-2, PMA or PMA plus PHA. abolished if a mutant oligonucleotide probe was used. The identity of the protein was confirmed by supershift analysis.
Dexamethasone prevents IL-2-, PMA-and PMA plus PHA-mediated up-regulation of MAT2A expression
Dexamethasone is known to inhibit T-lymphocyte activation and was shown to block the effect of IL-2 and phorbol ester on MAT2A expression [14] . We next examined whether the same occurs in Jurkat cells and what the mechanism might be. Figure  1 shows that dexamethasone treatment alone had no effect on the basal mRNA level of MAT2A but blocked the increase in MAT2A mRNA level after PMA treatment. Table 1 shows that c-Myb up-regulates MAT2A expression in activated Jurkat cells dexamethasone pretreatment prevented the IL-2-and PMAmediated increase in reporter activity driven by the MAT2A k571\j60 promoter-luciferase construct.
To see if dexamethasone's effect is mediated by c-Myb, we examined c-Myb mRNA level and c-Myb EMSA after dexamethasone treatment. Figure 1 shows that dexamethasone treatment alone had no effect on the basal mRNA level of c-Myb but blocked the increase in c-Myb mRNA level after PMA treatment. Finally, Figure 4 (B) shows that dexamethasone pretreatment prevented the increase in c-Myb nuclear binding after PMA\PHA treatment.
DISCUSSION
MAT is a critical cellular enzyme because it catalyses the only reaction that generates SAM. The MAT gene is one of 482 genes absolutely required for survival of an organism [1] . In mammals, two distinct genes code for the enzyme MAT [3] [4] [5] . MAT1A is a liver-specific gene that is expressed in the liver shortly before birth and becomes the major form of MAT as the liver matures [22, 23] . It is a marker for the differentiated or mature liver phenotype. In contrast, MAT2A is expressed in all non-hepatic tissues as well as during periods of rapid liver growth [3, 6, 17, [22] [23] [24] [25] [26] . Despite the importance of MAT2A, little is known about its transcriptional regulation. MAT2A gene expression appears to be influenced by the cell cycle, as evident from its induction during liver regeneration, malignant liver transformation and T-lymphocyte activation [10, 11, 17, [24] [25] [26] [27] . In all cases the mechanism involved in part increased transcription [11, 24, 27] . It has been speculated that the induction of MAT2A and MAT II may be a mechanism for the cell to provide an increased supply of SAM, the precursor to polyamine synthesis, which is required for cell growth [11] . Consistent with this notion, inhibition of SAM synthesis blocked T-lymphocyte proliferation [9] . Our laboratory has been interested in studying transcriptional regulation of MAT2A and has cloned a 1.3 kb 5'-flanking region of the human MAT2A gene [12] . In the current work we examined the molecular mechanism for the transcriptional up-regulation of MAT2A in Jurkat cells after treatment with IL-2, PMA or PMA plus PHA.
Using doses of IL-2, PMA or PMA\PHA similar to those that other investigators have reported either induce MAT2A expression in rat lymphoblasts [11] or activate Jurkat cells [14] , we first confirmed increased MAT2A expression in Jurkat cells. Analysis of reporter activity driven by the MAT2A promoter constructs revealed that the region between k571 and k270 of MAT2A is crucial for the stimulatory effect to occur. Of the multiple consensus binding sites for transcription factors, we focused on a putative c-Myb site (k350 to k333) because it is known that c-Myb expression is induced during T-lymphocyte activation [14] . A number of different approaches were then taken to critically examine the role of c-Myb in the IL-2-, PMAand PMA\PHA-mediated up-regulation of MAT2A expression. Specifically, nuclear binding to the c-Myb site of the MAT2A is increased after treatment of Jurkat cells with these agents. If the c-Myb site is mutated, both induction of the MAT2A promoter activity and c-Myb nuclear-binding activity were abolished. Overexpression of c-Myb in otherwise quiescent Jurkat cells also led to increased MAT2A promoter activity, an effect that was blocked if the c-Myb site was mutated. Finally, dexamethasone, a known inhibitor of T-lymphocyte activation, blocked the effect of these agents on MAT2A expression, MAT2A promoter activity, c-Myb nuclear binding and c-Myb expression. Collectively, these results demonstrate clearly that these agents modulate MAT2A expression in Jurkat cells via c-Myb. c-Myb is a transcription factor encoded by the c-Myb protooncogene and is best known as a regulator of cell growth and differentiation in haematopoietic cells [28] . c-Myb is highly expressed in immature haematopoietic cells, and the expression is strongly down-regulated during terminal differentiation [28] . Overexpression of c-Myb inhibits differentiation of haematopoietic precursor cells, while antisense-mediated ablation of c-Myb inhibits their proliferation [29] . Despite the strong link between c-Myb and proliferation, there remains a large void in understanding the relevant target genes for c-Myb. Binding sites for c-Myb have been identified in an increasing number of gene promoters, including those of mim-1, cdc-2, c-myc, bcl-2, T-cell receptor δ and γ chains, CD4 and lck [30] . However, establishing a direct link between candidate genes and growth control has been difficult. MAT2A is a gene that is linked directly to cell growth in both lymphocytes and hepatocytes. Thus it represents an important target gene for c-Myb in the regulation of cell growth.
IL-2 is the major mitogenic cytokine for T-cells [31] . IL-2 stimulation activates a number of secondary messengers, including tyrosine kinases, Ser\Thr kinases, adaptor proteins and small G-proteins. These secondary messengers, in turn, activate inducible transactivating factors including STATs (signal transduction and activators of transcription), NF-κB (nuclear factor κB) and CREB (cAMP-response-element-binding protein) [31] . Some of the genes that are IL-2-responsive may be regulated by these transactivating factors. IL-2 has also been shown to relieve transcriptional attenuation of c-Myb in human thymic blast cells [31] . Whatever the mechanism, it is well established that IL-2 induces c-Myb expression.
The effect of phorbol ester on lymphocyte proliferation and cMyb expression is more controversial. Farrar and Anderson suggested that activation of protein kinase C (PKC) by IL-2 is a crucial step in the signal transduction elicited by IL-2 [32] . This idea is supported by the findings that phorbol esters activate PKC and mimic some of the IL-2 actions, such as the induction of some genes and T-cell proliferation [33] . However, phorbol esters induce proliferation in some T-cell clones but not in others [34] , whereas IL-2 induces proliferation in all. Redondo and coworkers showed that there are two different pathways for T-cell proliferation, one PKC-dependent and the other PKC-independent [34] . Our study shows that, in Jurkat cells, the two pathways probably converge to result in activation of c-Myb and subsequently MAT2A expression.
Glucocorticoids are known inhibitors of lymphocyte activation [11] . Dexamethasone blocked the IL-2-and phorbol estermediated induction of MAT2A expression in lymphoblasts [11] . We have confirmed this in Jurkat cells as well. The molecular events that mediate dexamethasone's inhibitory effect on lymphocyte proliferation is unclear. Our data suggest the inhibitory effect of dexamethasone on MAT2A expression may be mediated by c-Myb. However, how dexamethasone blocks the IL-2-and PMA-mediated increase in c-Myb is unclear. It is likely that the effect is indirect, as dexamethasone by itself had no influence on c-Myb expression.
In summary, the present work demonstrates that IL-2, PMA and PMA\PHA induced MAT2A expression in Jurkat cells by increasing c-Myb expression, which trans-activates the MAT2A promoter by binding to the c-Myb site located at k350 to k333 of MAT2A. Dexamethasone blocked the effect of IL-2, PMA and PMA plus PHA on MAT2A expression by blocking the increase in c-Myb. Since MAT is the only enzyme that catalyses the synthesis of SAM, which is required for growth, we have identified MAT2A as an important target for c-Myb in the regulation of cell growth.
